TCT 2023 Late-Breaking Science Collection
Published: 09 January 2024
-
Views:
315
-
Likes:
7
-
Views:
315
-
Likes:
7
-
Up Next -
11m 22s -
6m 19sPart 3 | Session 5 WATCH-TAVR: WATCHMAN for Patients with AF Undergoing TAVR -
7m 14s
-
25m 48sPart 1 | Session 1 View from the Thoraxcenter: TCT 23 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
30m 36sPart 1 | Session 2 View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
8m 13sPart 2 | Session 1 5 Trials That Will Change My Practice With Dr Kendra Grubb Kendra J Grubb
-
14m 10sPart 2 | Session 2 5 Trials That Will Change My Practice With Dr Mirvat Alasnag Mirvat Alasnag
-
12m 36sPart 2 | Session 3 5 Trials That Will Change My Practice With Dr Bernardo Cortese Bernardo Cortese
-
7m 42sPart 3 | Session 1 5Y Outcomes From the PARTNER 3 Low-Risk Trial
-
6m 43sPart 3 | Session 2 AGENT IDE: AGENT Paclitaxel Coated Balloon Angioplasty for In-Stent Restenosis Robert Yeh
Overview
Stay up-to-date with our regular review series, View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this #TCT2023 edition they provide a short analysis of the most pertinent data from the late-breaking science presentations.
Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Highlights
Part 3
Interviews
About the episode
TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic.
The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid aortic anatomy and severe aortic stenosis, who are at low-risk for SAVR. All patients enrolled in the trial were treated with the system and were followed up at pre and post-procedure, discharge, 30 days, 1 year, and annually through 10 years. These results show the four-year outcomes of this patient group.
Findings suggest that in low-risk patients, the Evolut TAVR system had lower reported rates of death or disabling stroke compared to state-of-the-art surgery that are diverging each year to 4 years, as well as superior hemodynamics when compared to SAVR.
Interview Questions:
- What are the current unmet needs of TAVR Patients?
- Could you tell us a bit about the Medtronic TAVR System, including its unique features?
- What was the study design and patient population?
- What are the key findings?
- What are your take-home messages?
- What further study is still required, and what are the next steps?
Recorded remotely from Texas, 2023.
Editor: Jordan Rance
Video Specialist: Tom Green
Faculty Biographies
Michael J Reardon
Dr Michael J. Reardon holds the position of Clinical Professor of Cardiothoracic Surgery at MD Anderson Cancer Center and created the multi-institution, multidisciplinary cardiac tumor team with HMH and MDA.
He has served as elected president of the medical staff for the HMH and received numerous awards including the Overstreet Award and Noon Award. He currently holds the Allison Family Distinguished Chair of Cardiovascular Research and divides his time between building innovative clinical, research and educational programs.
Comments